

## CLEO Appoints First Key Opinion Leader to Support U.S. Market Entry

### Highlights

- **CLEO appoints its first U.S. Key Opinion Leader, Dr Nicholas Lambrou, a leading gynaecologic oncologist and surgical specialist**
- **Dr Lambrou to support clinical advocacy, publication development, and presentation of CLEO's technology at major U.S. scientific meetings**
- **KOL engagement represents a key U.S. market entry activity as a part of CLEO's commercialisation strategy for its Pre Surgical Ovarian Cancer Test.**

MELBOURNE, AUSTRALIA, 19<sup>th</sup> November 2025: Ovarian Cancer diagnostics company, **Cleo Diagnostics Limited (ASX:COV) (CLEO or the Company)** is pleased to announce the appointment of leading U.S. gynaecologic oncologist, Dr Nicholas Lambrou, as the Company's first Key Opinion Leader (**KOL**).

Dr Lambrou is a highly respected U.S. based surgeon, clinical advisor, and researcher with extensive expertise in oncology, gynaecologic surgery, and women's health. Dr. Lambrou completed his residency at the Johns Hopkins Hospital and University. After completing fellowship at the University of Miami, Dr. Lambrou served as associate professor and has authored or co-authored multiple peer-reviewed publications, book chapters and editorship. He has participated in the latest clinical trials in the treatments of gynaecologic cancers and is actively recruiting patients for CLEO's U.S. clinical trial. His appointment represents a major step in CLEO's U.S. market entry strategy with respect to early-adopter engagement, and clinical advocacy.

### Commenting on his KOL Appointment, Dr Nick Lambrou, said:

*"I am thrilled to join CLEO at such a pivotal point in its journey. Backed by more than 15 years of rigorous scientific research, CLEO's work has reached a point where it can now be translated into real clinical practice where it has the potential to make a profound difference. As a surgeon who confronts the diagnostic uncertainty around ovarian cancer every day, I see enormous value in a pre-surgical test that can bring greater accuracy, confidence, and clarity to women, doctors and gynaecologic oncologists. I look forward to working with the CLEO team to help introduce this innovation into the U.S. healthcare system and advance a new standard of care for women."*

Under the Agreement, Dr Lambrou will support the Company in the following activities:

- Clinical and medical review of CLEO's research, data, and publications
- Advisory input on data interpretation, manuscript development, and presentation materials
- Presentation of CLEO's research findings at scientific meetings and congresses in the U.S.
- Participation in CLEO's Advisory Board and other strategic consultation activities.

#### Cleo Diagnostics Ltd ASX:COV

Level 2, 480 Collins Street, Melbourne, VIC, 3000  
ACN 655 717 169 T +61 3 9614 0600 E office@cleodx.com

#### Directors

Chair and Non-Executive Director **Adrien Wing**  
Chief Executive Officer and Executive Director **Dr Richard Allman**  
Chief Scientific Officer and Executive Director **Dr Andrew Stephens**  
Non-Executive Director and Lead Medical Advisor **Professor Tom Jobling**  
Non-Executive Director **Lucinda Nolan**

This appointment strengthens CLEO's execution pathway as the Company prepares for the launch of its Pre-Surgical Ovarian Cancer Test next year. Establishing a network of respected U.S. KOL's is a core pillar of CLEO's early-market engagement strategy, supporting clinical validation, awareness-building, and early adoption among specialist clinicians.

Dr Lambrou's presence and influence within the U.S. healthcare ecosystem, particularly among gynaecologic oncologists, surgeons, and women's health centres, will play a central role in CLEO's market entry activities. His clinical expertise and visibility will help the Company accelerate introduction of its technology into the U.S. and provide independent, practice-based insights to support market education and uptake.

**Commenting on the KOL Appointment, CLEO's Chief Executive Officer, Dr Richard Allman, said:**

*"Appointing Dr Lambrou as our first KOL marks a meaningful milestone in our market-entry preparation. His clinical leadership, experience, and proximity to the U.S. market, being our largest commercial opportunity, will support CLEO's staged execution strategy, ensuring our technology is introduced with the right clinical voices, scientific credibility, and pathways for early adoption."*

The Company expects to expand its KOL and advisory network as it moves through key development, regulatory, and commercialisation milestones.

**-Ends-**

**This ASX announcement was authorised for release on behalf of the Cleo Diagnostics Ltd Board.**

For more information, contact:

**Richard Allman**  
Chief Executive Officer  
+613 9614 0600  
office@cleodx.com

**Dayna Louca**  
Head of Corporate Development  
+61 409 581 972  
dayna.louca@cleodx.com



Forward Looking Statements: This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of Cleo and certain of the plans and objectives of Cleo with respect to these items. These forward-looking statements are not historical facts but rather are based on Cleo's current expectations, estimates and projections about the industry in which Cleo operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Cleo, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Cleo cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Cleo only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Cleo will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

### About Cleo Diagnostics Ltd ASX:COV

Cleo Diagnostics (ASX:COV) is an Australian medical technology company developing a simple blood test for the early and accurate detection of ovarian cancer – a disease with the highest five-year mortality rate of all cancers affecting women, with 51% of patients dying within five years, primarily due to late diagnosis and the lack of effective screening tools. Each year, hundreds of thousands of women are diagnosed only after the disease has advanced, highlighting a critical unmet need for earlier detection.

CLEO's patented technology is based on the CXCL10 biomarker, supported by over 15 years of scientific research and development. CXCL10 is produced early and at high levels in ovarian cancer but is largely absent in benign disease, making it a powerful discriminator between malignant and non-malignant growths.

The Company is executing a staged development strategy, starting with a pre-surgical triage test, then expanding into recurrence monitoring and ultimately global screening – creating clear value inflection points along the ovarian cancer detection pathway. CLEO is currently conducting its pivotal clinical trial, with FDA submission and commercial launch expected next year, reinforcing its goal to redefine the standard of care and enable earlier, smarter, life-changing diagnosis for women worldwide.

